Patents by Inventor Tomasz Cierpicki

Tomasz Cierpicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170253611
    Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 3: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.
    Type: Application
    Filed: October 18, 2016
    Publication date: September 7, 2017
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li
  • THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170247391
    Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
    Type: Application
    Filed: September 8, 2015
    Publication date: August 31, 2017
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: 9505782
    Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 2: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: November 29, 2016
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li
  • Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: 9505781
    Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 4b: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 29, 2016
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay Hess, Duxin Sun, Xiaoqin Li
  • COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160137665
    Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 2: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 19, 2016
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li
  • COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160046647
    Abstract: The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine and thienopyridine class compounds and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin).
    Type: Application
    Filed: March 10, 2014
    Publication date: February 18, 2016
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay Hess, Duxin Sun, Xiaoqin Li
  • COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA
    Publication number: 20160045504
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Application
    Filed: March 23, 2015
    Publication date: February 18, 2016
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess
  • Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: 9216993
    Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 4: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: December 22, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li
  • Menin-MLL inhibitors and methods of use thereof
    Patent number: 9212180
    Abstract: The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, MLL-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, MLL-PTD and/or menin.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, VANDERBILT UNIVERSITY
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Sunil Kumar Upadhyay, Shaun R. Stauffer, Rocco D. Gogliotti, Timothy J. Senter
  • Compositions and methods for treatment of leukemia
    Patent number: 8993552
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: March 31, 2015
    Assignees: The Regents of The University of Michigan, University of Virginia Patent Foundation
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess
  • MENIN-MLL INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20140371239
    Abstract: The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, MLL-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, MLL-PTD and/or menin.
    Type: Application
    Filed: June 11, 2014
    Publication date: December 18, 2014
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Sunil Kumar Upadhyay, Shaun R. Stauffer, Rocco D. Gogliotti, Timothy J. Senter
  • COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140275070
    Abstract: The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine class compounds and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of MLL1 and MLL2 or menin).
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li
  • COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA
    Publication number: 20110065690
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Application
    Filed: September 3, 2010
    Publication date: March 17, 2011
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess